Logo image of RCKT

ROCKET PHARMACEUTICALS INC (RCKT) Stock Fundamental Analysis

NASDAQ:RCKT - Nasdaq - US77313F1066 - Common Stock - Currency: USD

10.47  -0.4 (-3.68%)

After market: 10.66 +0.19 (+1.81%)

Fundamental Rating

2

Taking everything into account, RCKT scores 2 out of 10 in our fundamental rating. RCKT was compared to 571 industry peers in the Biotechnology industry. RCKT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RCKT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RCKT has reported negative net income.
In the past year RCKT has reported a negative cash flow from operations.
In the past 5 years RCKT always reported negative net income.
RCKT had a negative operating cash flow in each of the past 5 years.
RCKT Yearly Net Income VS EBIT VS OCF VS FCFRCKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

RCKT's Return On Assets of -65.55% is on the low side compared to the rest of the industry. RCKT is outperformed by 62.70% of its industry peers.
RCKT has a Return On Equity of -78.26%. This is comparable to the rest of the industry: RCKT outperforms 52.58% of its industry peers.
Industry RankSector Rank
ROA -65.55%
ROE -78.26%
ROIC N/A
ROA(3y)-39.2%
ROA(5y)-32.4%
ROE(3y)-44.12%
ROE(5y)-37.05%
ROIC(3y)N/A
ROIC(5y)N/A
RCKT Yearly ROA, ROE, ROICRCKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCKT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCKT Yearly Profit, Operating, Gross MarginsRCKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, RCKT has more shares outstanding
Compared to 5 years ago, RCKT has more shares outstanding
Compared to 1 year ago, RCKT has an improved debt to assets ratio.
RCKT Yearly Shares OutstandingRCKT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
RCKT Yearly Total Debt VS Total AssetsRCKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

RCKT has an Altman-Z score of 4.67. This indicates that RCKT is financially healthy and has little risk of bankruptcy at the moment.
RCKT's Altman-Z score of 4.67 is amongst the best of the industry. RCKT outperforms 80.11% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that RCKT is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.06, RCKT is not doing good in the industry: 64.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 4.67
ROIC/WACCN/A
WACCN/A
RCKT Yearly LT Debt VS Equity VS FCFRCKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

RCKT has a Current Ratio of 6.05. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.
RCKT's Current ratio of 6.05 is fine compared to the rest of the industry. RCKT outperforms 61.28% of its industry peers.
RCKT has a Quick Ratio of 6.05. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.
RCKT has a Quick ratio of 6.05. This is in the better half of the industry: RCKT outperforms 61.63% of its industry peers.
Industry RankSector Rank
Current Ratio 6.05
Quick Ratio 6.05
RCKT Yearly Current Assets VS Current LiabilitesRCKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.60% over the past year.
EPS 1Y (TTM)14.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RCKT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.15% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.41%
EPS Next 2Y10.81%
EPS Next 3Y13.91%
EPS Next 5Y26.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RCKT Yearly Revenue VS EstimatesRCKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
RCKT Yearly EPS VS EstimatesRCKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RCKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RCKT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCKT Price Earnings VS Forward Price EarningsRCKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCKT Per share dataRCKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as RCKT's earnings are expected to grow with 13.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.81%
EPS Next 3Y13.91%

More info and screens

0

5. Dividend

5.1 Amount

RCKT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (2/21/2025, 8:00:01 PM)

After market: 10.66 +0.19 (+1.81%)

10.47

-0.4 (-3.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-06 2025-03-06/amc
Inst Owners104.13%
Inst Owner Change-97.41%
Ins Owners3.11%
Ins Owner Change20.89%
Market Cap1.11B
Analysts84.35
Price Target43.57 (316.14%)
Short Float %10.45%
Short Ratio6.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.62%
Min EPS beat(2)-1.16%
Max EPS beat(2)8.41%
EPS beat(4)3
Avg EPS beat(4)8.09%
Min EPS beat(4)-1.16%
Max EPS beat(4)20.15%
EPS beat(8)5
Avg EPS beat(8)5.41%
EPS beat(12)7
Avg EPS beat(12)2.91%
EPS beat(16)9
Avg EPS beat(16)-4.65%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.78%
PT rev (3m)-8.98%
EPS NQ rev (1m)2.5%
EPS NQ rev (3m)2.5%
EPS NY rev (1m)1.18%
EPS NY rev (3m)1.71%
Revenue NQ rev (1m)-96.41%
Revenue NQ rev (3m)-96.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-99.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.37
P/tB 4.19
EV/EBITDA N/A
EPS(TTM)-2.75
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-1.9
FCFYN/A
OCF(TTM)-1.81
OCFYN/A
SpS0
BVpS3.1
TBVpS2.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.55%
ROE -78.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.2%
ROA(5y)-32.4%
ROE(3y)-44.12%
ROE(5y)-37.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 113.89%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.05
Quick Ratio 6.05
Altman-Z 4.67
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)171.1%
Cap/Depr(5y)1690.38%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.33%
EPS Next Y3.41%
EPS Next 2Y10.81%
EPS Next 3Y13.91%
EPS Next 5Y26.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.84%
EBIT Next 3Y18.15%
EBIT Next 5YN/A
FCF growth 1Y-26.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.52%
OCF growth 3YN/A
OCF growth 5YN/A